Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381628 | 0.98 | PDGFRB (0.41) | PTPN11PDGFRBPDGFRADHFRKCNH2 | |
| SCHEMBL13125213 | 0.86 | NPC1 (0.41) | THRATHRBHPGDHTTMAPT | |
| SCHEMBL27158845 | 0.82 | PTPN11 (0.46) | PTPN11PDGFRBPDGFRAKCNH2HRH3 | |
| SCHEMBL27158932 | 0.80 | PTPN11 (0.44) | PTPN11PDGFRBPDGFRADHFRKCNH2 | |
| SCHEMBL381770 | 0.80 | RARG (0.58) | PDGFRBPDGFRADHFRPDK2MAPT | |
| SCHEMBL344736 | 0.79 | RARG (0.60) | PDK2 | |
| SCHEMBL382102 | 0.79 | PDGFRB (0.44) | PTPN11PDGFRBPDGFRAKCNH2HRH3 | |
| SCHEMBL382766 | 0.78 | RARG (0.65) | — | |
| SCHEMBL382430 | 0.78 | RARG (0.48) | KCNH2HRH3 | |
| SCHEMBL382740 | 0.78 | RARG (0.61) | PDGFRBPDGFRADHFRPDK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470871-B2 | Ligands that modulate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-06-25 | — | — | US | disclosed |
| US-20120258996-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-11 | — | — | US | disclosed |
| US-8227507-B2 | Ligands that modulate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-07-24 | — | — | US | disclosed |
| EP-1831149-B1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2012-01-25 | — | — | EP | disclosed |
| US-20100292296-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-18 | — | — | US | disclosed |
| US-7807708-B2 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | disclosed |
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-17 | — | — | US | disclosed |
| EP-1831149-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066978-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS, AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | RARB, RARA, RARG | PTPN11 513/4885PDGFRB 613/4885PDGFRA 459/4885 |
| US-20120258996-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | RARB, RARA, RARG | PTPN11 607/4885PDGFRB 630/4885PDGFRA 454/4885 |
| US-20100292296-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | RARB, RARA, RARG | PTPN11 607/4885PDGFRB 630/4885PDGFRA 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.